Kinase hinge binding scaffolds and their hydrogen bond patterns.

Protein kinases constitute a major class of intracellular signaling molecules, and describe some of the most prominent drug targets. Kinase inhibitors commonly employ small chemical scaffolds that form hydrogen bonds with the kinase hinge residues connecting the N- and C-terminal lobes of the catalytic domain. In general the satisfied hydrogen bonds are required for potent inhibition, therefore constituting a conserved feature in the majority of inhibitor-kinase interactions. From systematically analyzing the kinase scaffolds extracted from Pfizer crystal structure database (CSDb) we recognize that large number of kinase inhibitors of diverse chemical structures are derived from a relatively small number of common scaffolds. Depending on specific substitution patterns, scaffolds may demonstrate versatile binding capacities to interact with kinase hinge. Afforded by thousands of ligand-protein binary complexes, the hinge hydrogen bond patterns were analyzed with a focus on their three-dimensional configurations. Most of the compounds engage H6 NH for hinge recognition. Dual hydrogen bonds are commonly observed with additional recruitment of H4 CO upstream and/or H6 CO downstream. Triple hydrogen bonds accounts for small number of binary complexes. An unusual hydrogen bond with a non-canonical H5 conformation is observed, requiring a peptide bond flip by a glycine residue at the H6 position. Additional hydrogen bonds to kinase hinge do not necessarily correlate with an increase in potency; conversely they appear to compromise kinase selectivity. Such learnings could enhance the prospect of successful therapy design.

[1]  Paul A. Bartlett,et al.  Differential binding energy: a detailed evaluation of the influence of hydrogen-bonding and hydrophobic groups on the inhibition of thermolysin by phosphorus-containing inhibitors , 1991 .

[2]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[3]  L. Otterbein,et al.  N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. , 2006, Journal of medicinal chemistry.

[4]  P. Caron,et al.  Classifying protein kinase structures guides use of ligand‐selectivity profiles to predict inactive conformations: Structure of lck/imatinib complex , 2007, Proteins.

[5]  A. Caflisch,et al.  Current kinase inhibitors cover a tiny fraction of fragment space. , 2015, Bioorganic & medicinal chemistry letters.

[6]  Li Xing,et al.  Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804. , 2009, Biochemistry.

[7]  C. Grütter,et al.  Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. , 2008, Bioorganic & medicinal chemistry.

[8]  Jirí Cerný,et al.  Thermodynamic penalty arising from burial of a ligand polar group within a hydrophobic pocket of a protein receptor. , 2006, Journal of molecular biology.

[9]  J. Schellens,et al.  Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Rubicelia Vargas,et al.  How Strong Is the Cα−H···OC Hydrogen Bond? , 2000 .

[11]  Yusuke Nakamura,et al.  Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation. , 2012, ACS medicinal chemistry letters.

[12]  C. Paweletz,et al.  Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells , 2010, The Journal of Biological Chemistry.

[13]  P. Graczyk Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. , 2007, Journal of medicinal chemistry.

[14]  David R. Liu,et al.  Highly Specific, Bi-substrate-Competitive Src Inhibitors from DNA-Templated Macrocycles , 2011, Nature chemical biology.

[15]  Li Xing,et al.  Scaffold mining of kinase hinge binders in crystal structure database , 2013, Journal of Computer-Aided Molecular Design.

[16]  F. Uckun,et al.  Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Molecular Basis of X-linked Agammaglobulinemia* , 2001, The Journal of Biological Chemistry.

[17]  G. Blumenschein,et al.  Motesanib and advanced NSCLC: experiences and expectations , 2011, Expert opinion on investigational drugs.

[18]  Yu-Wei Chang,et al.  An enriched structural kinase database to enable kinome‐wide structure‐based analyses and drug discovery , 2010, Protein science : a publication of the Protein Society.

[19]  John Kuriyan,et al.  A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain , 2006, PLoS biology.

[20]  L. Tabernero,et al.  Biophysical and X-ray crystallographic analysis of Mps1 kinase inhibitor complexes. , 2010, Biochemistry.

[21]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[22]  D. Xie,et al.  X‐Ray Crystal Structure of Bone Marrow Kinase in the X Chromosome: A Tec Family Kinase , 2011, Chemical biology & drug design.

[23]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[24]  Arvin C Dar,et al.  Small molecule recognition of c-Src via the Imatinib-binding conformation. , 2008, Chemistry & biology.

[25]  J. Thornton,et al.  Satisfying hydrogen bonding potential in proteins. , 1994, Journal of molecular biology.

[26]  Mark R Player,et al.  Crystal Structure of the Tyrosine Kinase Domain of Colony-stimulating Factor-1 Receptor (cFMS) in Complex with Two Inhibitors* , 2006, Journal of Biological Chemistry.

[27]  J. Kuriyan,et al.  c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. , 2007, Structure.

[28]  Oliver Hantschel,et al.  Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. , 2006, Molecular cell.

[29]  Yusuke Nakamura,et al.  A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity. , 2015, Bioorganic & medicinal chemistry.

[30]  Alexander V Efimov,et al.  Relationship between intramolecular hydrogen bonding and solvent accessibility of side‐chain donors and acceptors in proteins , 2003, FEBS letters.

[31]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[32]  Rajiv Chopra,et al.  4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6. , 2010, Journal of medicinal chemistry.

[33]  Philip D. Jeffrey,et al.  Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a , 1998, Nature.

[34]  Arup K. Ghose,et al.  Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. , 2008, Journal of medicinal chemistry.

[35]  Kevin E. Riley,et al.  Insights into the strength and origin of halogen bonding: the halobenzene-formaldehyde dimer. , 2007, The journal of physical chemistry. A.